Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Grows By 48.5%

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the recipient of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 1,990,000 shares, a growth of 48.5% from the March 31st total of 1,340,000 shares. Based on an average daily volume of 987,100 shares, the short-interest ratio is currently 2.0 days.

Institutional Trading of Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC acquired a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned approximately 0.12% of Brainstorm Cell Therapeutics as of its most recent SEC filing. 14.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Brainstorm Cell Therapeutics in a report on Wednesday, March 27th. They issued a “sell” rating for the company.

Brainstorm Cell Therapeutics Stock Performance

Shares of NASDAQ BCLI remained flat at $0.53 during trading hours on Friday. The company had a trading volume of 266,201 shares, compared to its average volume of 977,687. The company has a 50-day moving average price of $0.48 and a two-hundred day moving average price of $0.33. Brainstorm Cell Therapeutics has a 12-month low of $0.13 and a 12-month high of $3.34.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings results on Monday, April 1st. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. Analysts forecast that Brainstorm Cell Therapeutics will post -0.28 earnings per share for the current year.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.